ARCA biopharma, Inc.
ARCA biopharma, Inc. is listed today as Oruka Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2015 | $52 M | Private placement after listing | $50 to $250 million | equity, options | SEC | |
| Jun 2013 | $1 M | Private placement after listing | Under $2 million | options | SEC | |
| Jan 2013 | $1 M | Private placement after listing | Under $2 million | equity, options | SEC | |
| Dec 2011 | $5 M | No. 1 | $2 to $10 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
ARCA biopharma, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2015).
SEC Form D · Jun 2015
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jun 2015
That is all the official record says: ARCA biopharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of ARCA biopharma, Inc. are on record.
Investors#
3 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2024) | SEC Form 3 |
| Fairmount Healthcare Co-Invest III L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2024) | SEC Form 3 |
| Fairmount Healthcare Fund II L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner, director (Form 3, 2024) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 6 investors.
Largest shareholders today
Institutions holding Oruka Therapeutics, Inc. shares, as of Sep 30, 2026.
- FMR LLC$845 M14.96%
- BlackRock, Inc.$434 M7.68%
- T. Rowe Price Investment Management, Inc.$366 M6.48%
- Venrock Adviser, LLC$346 M6.12%
- Fairmount Funds Management LLC$309 M5.46%
- Capital World Investors$286 M5.06%
- RTW Investments, LP$261 M4.63%
- State Street Corp$235 M4.15%
- Vanguard Capital Management LLC$220 M3.90%
- Paradigm Biocapital Advisors LP$208 M3.68%
- Franklin Templeton Inc$169 M3.00%
- Janus Henderson Group Ltd.$156 M2.76%
- Bellevue Group AG$137 M2.42%
- Vanguard Portfolio Management LLC$133 M2.35%
- Ra Capital Management, L.P.$129 M2.29%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Brian L. Selby | Executive officer | Jun 2015 |
| Christopher D. Ozeroff | Executive officer | Jun 2015 |
| Michael R. Bristow | Executive officer | Jun 2015 |
| Thomas A. Keuer | Executive officer | Jun 2015 |
| Patrick M. Wheeler | Executive officer | Jun 2013 |
| Dan J. Mitchell | Director | Jun 2015 |
| Linda S. Grais | Director | Jun 2015 |
| Michael R. Bristow | Director | Jun 2015 |
| Raymond L. Woosley | Director | Jun 2015 |
| Robert E. Conway | Director | Jun 2015 |
| Jean-Francois D. Formela | Director | Jun 2013 |
| John L. Zabriskie | Director | Jun 2013 |
| Linda D. Grais | Director | Jun 2013 |
| Burton E. Sobel | Director | Feb 2013 |
| Jean-Francois B. Formela | Director | Jan 2012 |
| Linda B. Grais | Director | Jan 2012 |
| Richard B. Brewer | Director | Jan 2012 |
Went public since 2012. Its SEC number is that of a company listed on a stock exchange.